NASDAQ:FRLN

Freeline Therapeutics Stock Forecast, Price & News

$4.76

+0.01 (+0.21 %)

(As of 07/30/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.72

▼

$4.90

50-Day Range

$4.66

▼

$11.00

52-Week Range

$4.26

▼

$21.69

Volume143,017 shs

Average Volume444,382 shs

Market Capitalization$170.60 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

30 days | 90 days | 365 days | Advanced Chart

Receive FRLN News and Ratings via Email

Sign-up to receive the latest news and ratings for Freeline Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Freeline Therapeutics

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Short Interest Update
July 30, 2021 | americanbankingnews.com

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Given Average Recommendation of "Buy" by Analysts
July 27, 2021 | americanbankingnews.com

Zacks: Analysts Anticipate Freeline Therapeutics Holdings plc (NASDAQ:FRLN) Will Announce Earnings of -$0.96 Per Share
July 25, 2021 | americanbankingnews.com

Freeline Therapeutics (NASDAQ:FRLN) vs. Surface Oncology (NASDAQ:SURF) Critical Survey
July 19, 2021 | americanbankingnews.com

Here is What Hedge Funds Think About Freeline Therapeutics Holdings plc (FRLN)
June 22, 2021 | finance.yahoo.com

Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
June 16, 2021 | finance.yahoo.com

Freeline Therapeutics Holdings PLC Sponsored ADR
June 10, 2021 | realmoney.thestreet.com

3 “Strong Buy” Stocks Under $10 With Triple-Digit Upside Potential
May 26, 2021 | finance.yahoo.com

Freeline Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 17, 2021 | finance.yahoo.com

Freeline to Participate at the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FRLN
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.freeline.life
Phone44-14-3890-6870
Employees236
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$6.96 per share
Price / Book0.68

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares35,840,000
Market Cap$170.60 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.81 out of 5 stars

3.4 Analyst's Opinion

Consensus Rating
Freeline Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $24.57, Freeline Therapeutics has a forecasted upside of 416.2% from its current price of $4.76.
Amount of Analyst Coverage
Freeline Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0 Community Rank

Outperform Votes
Freeline Therapeutics has received 20 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Freeline Therapeutics has received 3 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Freeline Therapeutics has received 86.96% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Freeline Therapeutics and other stocks. Vote “Outperform” if you believe FRLN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe FRLN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Freeline Therapeutics does not currently pay a dividend.
Dividend Growth
Freeline Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Freeline Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 32.84% of the stock of Freeline Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Freeline Therapeutics are expected to decrease in the coming year, from ($3.81) to ($3.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Freeline Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Freeline Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Freeline Therapeutics has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Freeline Therapeutics (NASDAQ:FRLN) Frequently Asked Questions

Is Freeline Therapeutics a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Freeline Therapeutics in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Freeline Therapeutics stock.
View analyst ratings for Freeline Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Freeline Therapeutics?

Wall Street analysts have given Freeline Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Freeline Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Freeline Therapeutics?

Freeline Therapeutics saw a drop in short interest during the month of July. As of July 15th, there was short interest totaling 34,400 shares, a drop of 37.3% from the June 30th total of 54,900 shares. Based on an average trading volume of 136,700 shares, the short-interest ratio is presently 0.3 days. Currently, 0.1% of the shares of the company are short sold.
View Freeline Therapeutics' Short Interest.

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) issued its quarterly earnings data on Sunday, May, 16th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by $0.20.
View Freeline Therapeutics' earnings history.

What price target have analysts set for FRLN?

9 equities research analysts have issued 1-year target prices for Freeline Therapeutics' shares. Their forecasts range from $17.00 to $30.00. On average, they anticipate Freeline Therapeutics' stock price to reach $24.57 in the next twelve months. This suggests a possible upside of 416.2% from the stock's current price.
View analysts' price targets for Freeline Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Freeline Therapeutics' key executives?

Freeline Therapeutics' management team includes the following people:

Ms. Theresa Marie Heggie, CEO & Director (Age 61)
Mr. Michael J. Parini, COO & Pres (Age 46)
Dr. Amit Nathwani M.D., Ph.D., Founder, Clinical & Scientific Adviser and Independent Director (Age 61)
Dr. Markus Horer Ph.D., Founder, CTO & Managing Director GmbH (Age 54)
Dr. Romuald Corbau Ph.D., Chief Scientific Officer (Age 52)
Mr. David S. Arrington, VP of Investor Relations & Corp. Communications
Mr. Stephen P. Diamond Jr., Sr. VP & Gen. Counsel (Age 49)
Dr. Jan Thirkettle Ph.D., Chief Devel. Officer (Age 49)
Mr. Eric Fink, Chief HR Officer (Age 44)
Dr. Gerard Short, Head of Clinical and Regulatory

Who are some of Freeline Therapeutics' key competitors?

Some companies that are related to Freeline Therapeutics include Molecular Partners (MOLN), Osiris Therapeutics (OSIR), Taysha Gene Therapies (TSHA), Passage Bio (PASG), Finch Therapeutics Group (FNCH), MeiraGTx (MGTX), Acumen Pharmaceuticals (ABOS), Cellectis (CLLS), DBV Technologies (DBVT), Talaris Therapeutics (TALS), Precision BioSciences (DTIL), Aligos Therapeutics (ALGS), Adaptimmune Therapeutics (ADAP), Poseida Therapeutics (PSTX) and Soaring Eagle Acquisition (SRNG).
View all of FRLN's competitors.

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Freeline Therapeutics investors own include Adobe (ADBE), BigCommerce (BIGC), Checkmate Pharmaceuticals (CMPI), CVS Health (CVS), Old Dominion Freight Line (ODFL), Oak Street Health (OSH), Rocket Companies (RKT), Shopify (SHOP), Zoom Video Communications (ZM) and Zymeworks (ZYME).

When did Freeline Therapeutics IPO?

(FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Freeline Therapeutics' stock symbol?

Freeline Therapeutics trades on the NASDAQ under the ticker symbol "FRLN."

How do I buy shares of Freeline Therapeutics?

Shares of FRLN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Freeline Therapeutics' stock price today?

One share of FRLN stock can currently be purchased for approximately $4.76.

How much money does Freeline Therapeutics make?

Freeline Therapeutics has a market capitalization of $170.60 million. The company earns $-96,320,000.00 in net income (profit) each year or ($6.81) on an earnings per share basis.

How many employees does Freeline Therapeutics have?

Freeline Therapeutics employs 236 workers across the globe.

What is Freeline Therapeutics' official website?

The official website for Freeline Therapeutics is www.freeline.life.

Where are Freeline Therapeutics' headquarters?

Freeline Therapeutics is headquartered at STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX.

How can I contact Freeline Therapeutics?

Freeline Therapeutics' mailing address is STEVENAGE BIOSCIENCE CATALYST GUNNELS WOOD ROAD STEVENAGE, HERTFORDSHIRE X0, SG12FX. The company can be reached via phone at 44-14-3890-6870 or via email at [email protected]

This page was last updated on 7/31/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here